ENTITY

Symbio Pharmaceuticals (4582 JP)

40
Analysis
Health Care • Japan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
•09 Oct 2018 11:49

Smartkarma’s Week that Was in JP/​KR: King Street Vs. Toshiba, Korea's Donki, and SKT Split

Below is the list of the Japan/Korea related posts put on the Smartkarma platform last week. It was a holiday week for both Japan and Korea. So, we...

Logo
434 Views
Share
•28 Sep 2018 20:14

Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy

Announcement – Symbio Pharmaceuticals (4582 JP) on September 27, 2018, announced that it has filed a partial change application for marketing...

•30 Aug 2018 09:22

Growth Drivers on Track – Operational Turnaround Expected in 2021

We reiterate our “Overweight” rating on the stock post 1H FY18 (YE Dec-18) earnings1H FY18 Results Highlights Symbio reported an increase in 1H...

•09 Apr 2018 19:29•Issuer-paid

SymBio Pharmaceuticals - Self-commercialization gains favor

With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...

Share
•06 Apr 2018 17:02•Issuer-paid

SymBio Pharmaceuticals - Self-commercialisation gains favour

With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...

Share
x